SEC Company Response from GSK (GSK) — Oct 26, 2005
GSK plc
Date: Oct. 26, 2005 · CIK: 0001131399 · Accession: 0000903423-05-000846
AI Filing Summary & Sentiment
Referenced dates: October 19, 2005, September 1, 2005
Letter
Division of Corporation Finance Securities and Exchange Commission Washington, D.C. 20549 United States Re: Comment Letter—GlaxoSmithKline PLC (“GSK”) Annual Report on Form 20-F for 2004
Dear Mr. Rosenberg:
I appreciate the opportunity to speak with your colleague, Sasha Parikh, earlier today in connection with your comment letter dated October 19, 2005 containing comments on GSK’s response letter dated September 1, 2005. As requested, this is a brief note to indicate that GSK intends to respond to those comments by November 25, 2005.
Although the comments are not extensive, the preparation of appropriate responses will require the involvement of a number of GSK executives and financial and legal department staff, as well as members of the GSK audit team from PricewaterhouseCoopers and outside counsel. Arranging for this involvement in order to meet the requested deadline would be difficult, particularly since many of these individuals are currently engaged in preparing GSK’s third quarter earnings release.
Mr. Jim B. Rosenberg, p. 2
You can reach either me, or my colleague Adam Schneider, at my number above. Please do not hesitate to contact us if you have any questions or if we can be of further assistance at this time.
Yours sincerely,
/s/ Sebastian R. Sperber
Sebastian R. Sperber
cc:
Ms. Sasha Parikh, Securities and Exchange Commission
Ms. Lisa Vanjoske, Securities and Exchange Commission
Mr. Christopher Buckley, GlaxoSmithKline PLC
Mr. Simon Friend, PricewaterhouseCoopers
Mr. Adam Schneider, Cleary Gottlieb Steen & Hamilton LLP
Show Raw Text
CORRESP
1
filename1.htm
Writer's Direct Dial: +44 (0) 207 614 2237
E-Mail: ssperber@cgsh.com
October 26, 2005
BY EDGAR
Mr. Jim B. Rosenberg
Senior Assistant Chief Accountant
Division of Corporation Finance
Securities and Exchange Commission
Washington, D.C. 20549
United States
Re:
Comment Letter—GlaxoSmithKline PLC (“GSK”) Annual Report on Form 20-F for 2004
Dear Mr. Rosenberg:
I appreciate the opportunity to speak with your colleague, Sasha Parikh, earlier today in connection with your comment letter dated October 19, 2005 containing comments on GSK’s response letter dated September 1, 2005. As requested, this is a brief note to indicate that GSK intends to respond to those comments by November 25, 2005.
Although the comments are not extensive, the preparation of appropriate responses will require the involvement of a number of GSK executives and financial and legal department staff, as well as members of the GSK audit team from PricewaterhouseCoopers and outside counsel. Arranging for this involvement in order to meet the requested deadline would be difficult, particularly since many of these individuals are currently engaged in preparing GSK’s third quarter earnings release.
Mr. Jim B. Rosenberg, p. 2
You can reach either me, or my colleague Adam Schneider, at my number above. Please do not hesitate to contact us if you have any questions or if we can be of further assistance at this time.
Yours sincerely,
/s/ Sebastian R. Sperber
Sebastian R. Sperber
cc:
Ms. Sasha Parikh, Securities and Exchange Commission
Ms. Lisa Vanjoske, Securities and Exchange Commission
Mr. Christopher Buckley, GlaxoSmithKline PLC
Mr. Simon Friend, PricewaterhouseCoopers
Mr. Adam Schneider, Cleary Gottlieb Steen & Hamilton LLP